Follow The Filings

ARWR Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals earnings company data as of 4:49 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 24 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ARWR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ARWR insider trades
  • None no insider bought on the open market
  • $2.7M sold by 3 insiders outside a trading plan
  • $10M sold by 8 insiders under 10b5-1 plans
  1. Michael S Perry Director
    Sale
    $1M 11,600 shares at $87.30 9.4% of stake
    Traded Aug 18 Filed Aug 20
    ↗
  2. Adeoye Y Olukotun Director
    Sale
    $174K 2,000 shares at $86.96 6% of stake
    Traded Aug 18 Filed Aug 20
    ↗
  3. Hongbo Lu Director
    Planned sale
    $228K 2,970 shares at $76.88 5.4% of stake
    Traded May 12 Filed May 14
    ↗
  4. James C Hamilton Chief Medical Officer
    Planned sale
    $750K 10,000 shares at $75.00 4.2% of stake
    Traded Apr 23 Filed Apr 24
    ↗
  5. James C Hamilton Chief Medical Officer
    Planned sale
    $642K 10,000 shares at $64.19 4% of stake
    Traded Mar 5 Filed Mar 9
    ↗
  6. Patrick O'Brien COO
    Planned sale
    $615K 9,755 shares at $63.03 2% of stake
    Traded Jan 5 Filed Jan 5
    ↗
  7. Mauro Ferrari Director
    Planned sale
    $527K 7,530 shares at $70.00 9.8% of stake
    Traded Dec 26, 2025 Filed Dec 30, 2025
    ↗
  8. Christopher Richard Anzalone CEO
    Planned sale
    $3.6M 51,726 shares at $69.13 1.3% of stake
    Traded Dec 29, 2025 Filed Dec 30, 2025
    ↗
  9. Victoria Vakiener Director
    Planned sale
    $679K 10,040 shares at $67.68 22% of stake
    Traded Dec 19, 2025 Filed Dec 23, 2025
    ↗
  10. William D. Waddill Director
    Planned sale
    $566K 8,367 shares at $67.65 13% of stake
    Traded Dec 19, 2025 Filed Dec 23, 2025
    ↗
  11. Christopher Richard Anzalone CEO
    Planned sale
    $1.8M 26,031 shares at $68.04 0.7% of stake
    Traded Dec 19–22 Filed Dec 23, 2025
    ↗
  12. Adeoye Y Olukotun Director
    Planned sale
    $677K 10,000 shares at $67.66 23% of stake
    Traded Dec 19, 2025 Filed Dec 23, 2025
    ↗
  13. Michael S Perry Director
    Sale
    $992K 16,250 shares at $61.03 12% of stake
    Traded Dec 5, 2025 Filed Dec 9, 2025
    ↗
  14. Mauro Ferrari Director
    Sale
    $493K 8,750 shares at $56.39 11% of stake
    Traded Nov 28, 2025 Filed Dec 1, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 35 sales to cover taxes, 12 stock grants, 10 gifts, and 2 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.